AstraZeneca announced the launch of Bydureon BCise (exenatide extended-release) injectable suspension as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 

Bydureon BCise is a new formulation of Bydureon (exenatide extended-release) that is supplied in a once-weekly, single-dose autoinjector device that comes prefilled with a pre-attached hidden needle. As the product is intended for self-administration, clinicians should train patients on proper mixing and injection technique to ensure the product is adequately mixed and a full dose is delivered.

Courtesy of AstraZeneca

Bydureon BCise, a glucagon-like peptide-1 (GLP-1) receptor agonist, is available in single-dose autoinjectors containing 2mg exenatide in 0.85mL vehicle in 4-count cartons. It is not recommended as first-line therapy for patients inadequately controlled on diet and exercise.

Related Articles

Reference

US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes [press release]. AstraZeneca; October 23, 2017. Accessed January 16, 2018.

This article originally appeared on MPR